Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011

Breast Cancer Research and Treatment

Volumn 170, Issue 2, 2018, Pages 361-371

  Wilson, Lauren E ^a   Pollack, Craig Evan ^b   Greiner, Melissa A ^a   Dinan, Michaela A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Biomarkers; Breast neoplasms; Chemotherapy; Gene expression profiling; Genetic testing; Physicians ; Practice patterns; SEER program; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

21 GENE RECURRENCE SCORE; ADJUVANT THERAPY; AGED; ARTICLE; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER THERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENDER; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; JOB EXPERIENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ONCOLOGIST; MEDICAL SOCIETY; MEDICARE; ONCOLOGIST; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SURGEON; SURGICAL ONCOLOGY; UNITED STATES; VERY ELDERLY; BREAST TUMOR; CANCER STAGING; GENETICS; HISTORY; ODDS RATIO; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENETIC TESTING; HISTORY, 21ST CENTURY; HUMANS; MEDICARE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PRACTICE PATTERNS, PHYSICIANS'; SEER PROGRAM; UNITED STATES;

EID: 85043683301     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-018-4746-6     Document Type: Article

References (43)

1. Győrffy B, Hatzis C, Sanft T, Hofstatter E, Aktas B, Pusztai L (2015) Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res 17:11
2. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734
3. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI (2008) Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196(4):527–529
4. Albanell J, González A, Ruiz-Borrego M, Alba E, García-Saenz JA, Corominas JM, Burgues O, Furio V, Rojo A, Palacios J, Bermejo B, Martínez-García M, Limon ML, Muñoz AS, Martín M, Tusquets I, Rojo F, Colomer R, Faull I, Lluch A (2012) Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 23(3):625–631
5. Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY (2013) Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation. Breast J 19(3):269–275
6. Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH (2015) Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among Medicare beneficiaries with early-stage breast cancer, 2005–2009. JAMA Oncol 1(8):1098–1109
7. Harris L, Ismaila N, McShane LM, Andre F, Coliyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF, American Society of Clinical Oncology (2016) Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34(10):1134–1150
8. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site: breast, version 3. http://www.nccn.org
9. Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH (2015) Initial trends in the use of the 21-gene recurrence score assay for patients with breast cancer in the Medicare population, 2005-2009. JAMA Oncol 1(2):158–166
10. DeFrank JT, Salz T, Reeder-Hayes K, Brewer NT (2013) Who gets genomic testing for breast cancer recurrence risk? Public Health Genomics 16(5):215–222
11. Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O’Regan RM (2012) 21-gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796
12. Harrold LR, Field TS, Gurwitz JH (1999) Knowledge, patterns of care, and outcomes of care for generalists and specialists. J Gen Intern Med 14(8):499–511
13. De Smet BD, Fendrick AM, Stevenson JG, Bernstein SJ (2006) Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited. J Gen Intern Med 21(7):694–697
14. Hirth RA, Fendrick AM, Chernew ME (1996) Specialist and generalist physicians’ adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Med Care 34(12):1199–1204
15. Rappaport KM, Forrest CB, Holtzman NA (2004) Adoption of liquid-based cervical cancer screening tests by family physicians and gynecologists. Health Serv Res 39(4 Pt 1):927–948
16. Kimmick GG, Camacho F, Mackley HB, Kern T, Yao N, Matthews SA, Fleming S, Lipscomb J, Liao J, Hwang W, Anderson RT (2015) Individual, area, and provider characteristics associated with care received for stages I to III breast cancer in a multistate region of Appalachia. J Oncol Pract 11(1):e9–e18
17. Thompson CA, Gomez SL, Chan A, Chan JK, McClellan SR, Chung S, Olson C, Nimbal V, Palaniappan LP (2014) Patient and provider characteristics associated with colorectal, breast, and cervical cancer screening among Asian Americans. Cancer Epidemiol Biomarkers Prev 23(11):2208–2217
18. Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI (2009) Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 115(17):3848–3857
19. Ayanian JZ, Guadagnoli E (1996) Variations in breast cancer treatment by patient and provider characteristics. Breast Cancer Res Treat 40(1):65–74
20. McLaughlin JM, Balkrishnan R, Paskett ED, Kimmick GG, Anderson RT (2009) Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in Medicaid-enrolled patients. J Natl Med Assoc 101(11):1112–1118
21. Surveillance, Epidemiology, and End Results Program. Overview of the SEER program. http://seer.cancer.gov/about/overview.html. Accessed 17 Apr 2015
22. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3-18
23. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267
24. Krumholz HM, Wang Y, Mattera JA, Wang Y, Han LF, Ingber MJ, Roman S, Normand SL (2006) An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 113(13):1693–1701
25. O’Brien RM (2007) A caution regarding rules of thumb for variance inflation factors. Qual Quan 41:673–690
26. Harrell FE Jr (2001) Multivariable modeling strategies. In: Harrell FE (ed) Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, New York, pp 53–85
27. Kim C, McEwen LN, Gerzoff RB, Marrero DG, Mangione CM, Selby JV, Herman WH (2005) Is physician gender associated with the quality of diabetes care? Diabetes Care 28(7):1594–1598
28. Tsugawa Y, Jena AB, Figueroa JF, Orav EJ, Blumenthal DM, Jha AK (2017) Comparison of hospital mortality and readmission rates for medicare patients treated by male vs female physicians. JAMA Intern Med 177(2):206–213
29. Berthold HK, Gouni-Berthold I, Bestehorn KP, Böhm M, Krone W (2008) Physician gender is associated with the quality of type 2 diabetes care. J Intern Med 264(4):340–350
30. Baumhäkel M, Müller U, Böhm M (2009) Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 11(3):299–303
31. Frank E, Harvey LK (1996) Prevention advice rates of women and men physicians. Arch Fam Med 5(4):215–219
32. Franks P, Clancy CM (1993) Physician gender bias in clinical decision making: screening for cancer in primary care. Med Care 31(3):213–218
33. Lurie N, Slater J, McGovern P, Ekstrum J, Quam L, Margolis K (1993) Preventive care for women. Does the sex of the physician matter? N Engl J Med 329(7):478–482
34. Bertakis KD, Helms LJ, Callahan EJ, Azari R, Robbins JA (1995) The influence of gender on physician practice style. Med Care 33(4):407–416
35. Roter DL, Hall JA (2004) Physician gender and patient-centered communication: a critical review of empirical research. Annu Rev Public Health 25:497–519
36. Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes K, Wheeler SB (2016) Oncologists’ barriers and facilitators for oncotype DX use: qualitative study. Int J Technol Assess Health Care 32(5):355–361
37. Jefferson L, Bloor K, Birks Y, Hewitt C, Bland M (2013) Effect of physicians’ gender on communication and consultation length: a systematic review and meta-analysis. J Health Serv Res Policy 18(4):242–248
38. Henderson JT, Weisman CS (2001) Physician gender effects on preventive screening and counseling: an analysis of male and female patients’ health care experiences. Med Care 39(12):1281–1292
39. Choudhry NK, Fletcher RH, Soumerai SB (2005) Systematic review: the relationship between clinical experience and quality of health care. Ann Intern Med 142(4):260–273
40. Patel MR, Chen AY, Roe MT, Ohman EM, Newby LK, Harrington RA, Smith SC Jr, Gibler WB, Calvin JE, Peterson ED (2007) A comparison of acute coronary syndrome care at academic and nonacademic hospitals. Am J Med 120(10):40–46
41. Veenstra CM, Epstein AJ, Liao K, Griggs JJ, Pollack CE, Armstrong K (2015) Hospital academic status and value of care for nonmetastatic colon cancer. J Oncol Pract 11(3):e304–e312
42. Ayanian JZ, Weissman JS (2002) Teaching hospitals and quality of care: a review of the literature. Milbank Q 80(3):569–593
43. Taylor DH Jr, Whellan DJ (1999) Sloan FA (1999) Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries. N Engl J Med 340(4):293–299